Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset——Joint poster presentation with Bachem to ...

Presentation Date/Time: Saturday, December 7, 2024, 5:30 p.m. PT Presenting Speaker: Alissa Brandes, Ph.D.

The poster presentation details are as follows: Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster II Publication Number: 2881 Title: MP0533 (CD33 x CD123 ...

AstraZeneca and TotalEnergies are among the stocks that fell into undervalued territory. We sell different types of products and services to both investment professionals and individual investors ...

-- Analysis of biopsies by AI-based Digital Pathology (qFibrosis®, Histoindex) corroborated the extent of improvement in ...

The poster to be presented at ASH 2024 will provide a clinical update of the ongoing first-in-human dose-escalation phase 1/2a study of MP0533 in patients with relapsed/refractory acute myeloid ...

allowing for control of tumors in vivo without the need for exogenous or engineered cytokines – – Posters include demonstration of advances in gene editing and transgene design that enable greater ...

Poster presentations across all programs, including updates from ongoing clinical studies and new translational data in preclinical models supporting use in existing and additional indications ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent ...